Treatment of central serous chorioretinopathy with beta-blocker metipranolol

The purpose of this study was to evaluate the effect of the systemically administered betablocker metipranolol on the course of central serous chorioretinopathy (CSC). A prospective double-blind study involving 48 patients with a first attack of CSC not exceeding two weeks and who agreed to the follow-up ophthalmology examinations every week. The group was divided into a metipranolol group (n=23), receiving 10 mg of drug twice per day and a placebo group (n=25). The outcome measure was time in weeks from drug intervention (metipranolol vs. placebo) to reattachment of macula neuroepithelium. There was no statistically significant difference in duration of CSC in patients who used metipranolol and those who used placebo (P=0.341). In a prospective double-blind study, we found no effect of the betablocker metipranolol on the duration of central serous chorioretinopathy.